[Nephrotoxicity of a Short Hydration Method for the Cisplatin Regimen in Patients with Gastric Cancer].
S-1 plus cisplatin(CDDP)has been a key regimen for advanced gastric cancer treatment. However, CDDP confers dose-limiting nephrotoxicity, requires a hospital stay for conventional massive hydration, and reduces patients' quality of life. We evaluated the nephrotoxicity of CDDP combination chemotherapy in an outpatient setting with short hydration for gastric cancer and investigated the feasibility of the short hydration method. Twenty-nine gastric cancer patients aged under 75 years with creatinine clearance rate >40mL/min and who received S-1 plus CDDP(60mg/m2)were recruited. Intravenous hydration was administered at 1,900 mL with magnesium and a diuretic. Any renal dysfunction over 5 courses of chemotherapy was analyzed. The majority(24/29)of patients could receive outpatient chemotherapy. The highest serum creatinine Grade in each course was Grade 1, and none of the patients developed creatinine toxicity of Grade 2 or higher over 5 courses of chemotherapy. An elevation in eGFR grade was found in 51.7%(15/29)patients; in 13 of those patients, the escalation was of at least 1 Grade. The short hydration method is feasible for gastric cancer patients receiving chemotherapy including CDDP in an outpatient setting.